Icagen, Inc.

Pfizer Corporation

Shulan Zhou

Brian Edward Marron

Christopher William West

Christopher John Markworth

David James Rawson

Nigel Alan Swain

Robert Ian Storer

Paul Anthony Stupple

Serge Beaudoin

David Simon Millan

Michael Christopher Laufersweiler

Steven Michael Reister

Kosuke Sasaki

Xiaodong Wang

Alan Bradley Fulp

Darrick Seconi

Matthew Scott Johnson

The invention relates to new sulfonamide Nav1.7 inhibitors and pharmaceutically acceptable salts thereof, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.

Sulfonamide compounds

The present invention relates to compounds of the formula and pharmaceutically acceptable salts, solvates or tautomers thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds, and the uses of such compounds, in particular for the treatment of pain.

Sulfonamide derivatives

Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted sulfonamides, compositions comprising these compounds, as well as methods of using these compounds or compositions in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. The compounds, compositions and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.

Sodium channel inhibitors

Growing community of inventors

Durham, NC, United States of America

Shulan Zhou